Related Experiment Video
Updated: Jan 2, 2026
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
Dosimetry of ruthenium-106 ophthalmic applicators with thin layer thermoluminescence dosimeters - Clinical quality
Fabian Krause1, Maja Möller1, Franziska Risske1
1University Medical Center Schleswig-Holstein, Department of Radiotherapy, Kiel, Germany (Full postal address: University Medical Center Schleswig-Holstein, Department of Radiotherapy, Karl-Lennert-Krebscentrum Nord, Feldstr. 21, 24105 Kiel), Germany.
Abstract:
Ruthenium-106 ophthalmic applicators have proven to be effective when using beta emitters in brachytherapy. For dose calculations , typically, the dosimetric reference data given by the manufacturer are used. An additional check of the applicators is usually not provided. However, the medical physicist is responsible for correct dosimetry in the clinic; therefore dosimetric verification is desirable. Despite the fact that the use of beta-ray emitting sealed brachytherapy sources is a safe treatment method, errors can occur (Kaulich et al., 2004). Hence, a method for absolute dose measurements based on the use of thin layer MCP-N-thermoluminescence detectors (TLD Poland, Krakow, Poland) is described in this study. A custom-made polymethyl methacrylate (PMMA)- based phantom was developed for this study. The surface of the phantom was designed to fit with spherical shells of ruthenium-106 ophthalmic applicators (e.g. applicator type CCA, CCB and CIA by Eckert & Ziegler BEBIG GmbH, Berlin, Germany) studied in this work. To verify the reference data from the source certificates, absolute point dose values were measured at different phantom depths with the thermoluminescence detectors and compared to the certificate values. Calibrations of the thermoluminescence detectors were performed in a water phantom with a 6 MV CLINAC (Artiste, Siemens Medical, Erlangen, Germany) before. A comparison with scintillator measurement results given by the manufacturer in the applicator certificate shows the measurement series of absolute dose using MCP-N thin layer detectors being in good accordance with the values of the applicator certificate. The dose values calculated with the source certificate can be confirmed with a maximum deviation of 6.5%. Further, it can be shown that compared to TLD-100, the use of MCP-N thermoluminescence detectors is an advantage, when calibrating with 6 MV photons. The phantom measuring procedure presented in this study provides a practice-oriented realization for quality control of ruthenium-106 ophthalmic applicators in clinical routine The phantom seems capable of performing periodic system tests, as well as controlling the introduction of new applicators delivered by the manufacturer.
